Zhongchao Inc. (ZCMD): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at Zhongchao Inc. as they navigate a tough spot: their H1 2025 revenue cratered by 46.02% to just $5.60M, which is concerning when you see their 2024 Cost of Revenue was $6.953M. Honestly, this means we need to look past the headlines and really dissect their core strategy-the Product focus on MDMOOC and patient services, their China-centric Place, their trust-building Promotion, and how they are pricing in this challenging environment. I've broken down the four P's for you below, mapping out exactly where Zhongchao Inc. is placing its bets to reverse this trend. Let's see if their late 2025 marketing mix holds up to scrutiny.

Zhongchao Inc. (ZCMD) - Marketing Mix: Product

The product element for Zhongchao Inc. (ZCMD) centers on healthcare information, education, training, and patient management services, with patented drug sales forming a separate revenue stream.

The company's offerings are delivered through several distinct channels and services:

• - MDMOOC online platform for healthcare professional education, operating via mdmooc.org.
• - Patient management services for major diseases like oncology and Systemic Lupus Erythematosus (SLE), provided under the Zhongxun brand.
• - Sales of Patented Drugs, which constitute a distinct revenue segment within the overall business.
• - Clinical practice training and interactive case study content, offered alongside customized medical courses and academic workshops.

The company serves healthcare professionals, nurses, doctors, and other healthcare workers, as well as enterprises, non-for-profit organizations, and medical journals.

Financial performance context for the product offerings, based on the latest available figures, shows a challenging revenue trajectory. The total revenue for the last twelve months ending June 30, 2025, was $13.12M, representing a year-over-year decrease of -24.64%. For the half year ending June 30, 2025, revenue was $5.60M, marking a significant drop of -46.02% compared to the prior period. The Q2 2025 quarterly revenue was reported as $2.80M.

Specific service metrics provide insight into the patient management component. As of a report from approximately one year ago, Zhongchao Inc. announced supporting over 7,000 SLE patients, involving approximately 130,000 units of medications dispensed. The overall revenue trend shows a total slide of -2.7% over the last three years.

Here is a summary of key financial and operational metrics relevant to the product portfolio as of late 2025:

The educational products, including the MDMOOC platform and interactive case studies, are key to the service delivery model. The company provides continuing education courses, open classes on popular medical topics, and articles/short videos with educational healthcare content. The platform is used to support disease management models, such as for lung cancer patients.

Zhongchao Inc. (ZCMD) - Marketing Mix: Place

The Place strategy for Zhongchao Inc. (ZCMD) is fundamentally anchored in the People's Republic of China, reflecting its focus on serving the domestic healthcare professional and patient ecosystem. The distribution model is overwhelmingly digital-first, supported by targeted physical engagements.

The core of the distribution network is digital, centered on the MDMOOC brand services. This digital infrastructure is designed to deliver healthcare information, education, and training products directly to the intended users, which include medical associations, hospitals, and individual healthcare professionals.

Key elements of the Place strategy and associated figures are:

• - Primary operations are concentrated within the People's Republic of China.
• - Distribution is digital-first via the MDMOOC mobile app and website, www.mdmooc.org.
• - Utilizes Chinese social media platforms like WeChat mini programs for patient outreach, specifically the Zhongxun brand IT system's WeChat mini program and the Zhongxin Health WeChat mini program.
• - Onsite presence maintained through academic conferences and workshops, alongside online services.

The scale of the digital and service distribution can be contextualized by the following figures, though specific 2025 platform user metrics for MDMOOC were not publicly itemized:

The digital channels serve a market with significant penetration; as of early 2025, China had 1.11 billion internet users, representing 78.0 percent of the total population, and 1.08 billion social media users, equating to 76.5 percent of the population. Zhongchao Inc. (ZCMD) leverages this broad digital access for its professional education platform. The company's headquarters location is Shanghai, Shanghai. As of December 2, 2025, the stock price was $0.5862.

The distribution strategy relies on direct engagement with medical entities, including medical associations, journals, foundations, and hospitals, through both the online platform and onsite academic conferences and workshops.

Zhongchao Inc. (ZCMD) - Marketing Mix: Promotion

Promotion activities for Zhongchao Inc. (ZCMD) focus on patient support, professional education, and broad health communication partnerships. The company consolidates operations of Shanghai Zhongxin Medical Technology Co., Ltd. ('Zhongxin'), which executes many patient-facing programs.

The medication assistance service for Systemic Lupus Erythematosus (SLE) patients provides concrete figures on direct patient support:

Strategic cooperation with Ximalaya for health knowledge popularization is a key communication tactic. This agreement, signed in May 2023, is set to span the next three years for joint efforts in health communications. At the time of the agreement, Ximalaya's average monthly active users across all scenarios reached 282 million as of the first three quarters of 2022.

Partnerships with medical foundations and associations for disease support are part of the broader strategy, facilitated by Zhongxin's technical service platform connecting hospitals, pharmacies, corporations, and non-profit organizations.

Focus on professional education to build brand trust with doctors is supported through the provision of specific content types:

• Continuing education courses.
• Articles with educational healthcare content.
• Short videos with educational healthcare content.

For financial context as of late 2025, Zhongchao Inc. reported unaudited interim financial statements for the six months ending June 30, 2025. The total revenues for that period were $5.6 million, and the company reported a net loss of $862,319. The current market capitalization stands at $27.78M.

Finance: draft 13-week cash view by Friday.

Zhongchao Inc. (ZCMD) - Marketing Mix: Price

You're looking at the pricing structure for Zhongchao Inc. (ZCMD) as of late 2025. Pricing here isn't just about setting a sticker price; it's about navigating significant top-line pressure while maintaining a competitive stance in the healthcare information and services space. The core challenge is ensuring the price point reflects the perceived value of their education and patient management services, especially when financial performance has been challenging.

Here's a look at the hard numbers shaping the pricing strategy right now:

• - Revenue for the first half of 2025 was $5.60M, a significant decline of -46.02%.
• - Pricing model is split between service fees and drug sales margins.
• - The Price-to-Sales (P/S) ratio was elevated at 2.3x as of June 2025.
• - Pricing must offset a high Cost of Revenue, which was $6.953M in 2024.

The necessity to cover costs is clear when you look at the income statement structure. Effective pricing must account for the cost base, which has been substantial relative to recent sales figures. To be fair, the market seems to be pricing in a potential turnaround, given that elevated P/S ratio, but the underlying revenue trend suggests caution is warranted.

The pricing strategy must also consider the company's overall valuation context. While the June 2025 P/S was 2.3x, more recent trailing twelve months (TTM) data suggests a P/S ratio of 0.76, indicating market perception of sales value has shifted. This fluctuation directly impacts how aggressively or defensively Zhongchao Inc. can price its service packages and drug-related margins.

Here are a few other financial data points that frame the pricing environment for Zhongchao Inc.:

• - Trailing Twelve Months Revenue stands at $13.12M.
• - The stock price as of December 4, 2025, was $0.608.
• - The 52-week stock price range is between a low of $0.537 and a high of $2.50.
• - The company maintains a net cash position of approximately $15.01 million.
• - Shares outstanding total 25.39 million.

Any financing options or credit terms offered would need to be structured carefully, especially given the negative operating margin of -8.91% on a TTM basis. Finance: draft 13-week cash view by Friday.